Health & Beauty

The FINANCIAL -- Adults with obesity treated with semaglutide 0.4 mg administered once-daily via subcutaneous injections lost up to 13.8% of their body weight after 52 weeks in a phase 2 trial, significantly more than those treated with placebo who lost 2.3% of their body weight. An oral presentation of data from this trial investigating the safety and efficacy of semaglutide as a potential ...